-
EP4008330
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4008330
| EP4008330 - COMBINED INHIBITION OF AMINO ACID TRANSPORTERS FOR INHIBITING HUMAN PLASMACYTOID DENDRITIC CELL ACTIVITY DURING AUTOIMMUNITY [Right-click to bookmark this link] | Status | The application has been refused Status updated on 07.10.2022 Database last updated on 31.08.2024 | |
| Former | The application has been published Status updated on 06.05.2022 | Most recent event Tooltip | 07.10.2022 | Refusal of application | published on 09.11.2022 [2022/45] | Applicant(s) | For all designated states Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Hofgartenstraße 8 80539 München / DE | [2022/23] | Representative(s) | Arth, Hans-Lothar ABK Patent Attorneys Jasminweg 9 14052 Berlin / DE | [2022/23] | Application number, filing date | 20212332.9 | 07.12.2020 | [2022/23] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP4008330 | Date: | 08.06.2022 | Language: | EN | [2022/23] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 01.09.2021 | Classification | IPC: | A61K31/517, A61K31/519, A61K31/635, A61P3/10, A61P17/00, A61P19/02, A61P19/04, A61P37/00, A61P43/00, A61K31/4402 | [2022/23] | CPC: |
A61P3/10 (EP);
A61K31/4402 (EP);
A61K31/517 (EP);
A61K31/519 (EP);
A61K31/635 (EP);
A61P17/00 (EP);
A61P19/02 (EP);
A61P19/04 (EP);
A61P37/00 (EP);
A61P43/00 (EP)
(-)
| C-Set: |
A61K31/4402, A61K2300/00 (EP);
A61K31/517, A61K2300/00 (EP);
A61K31/519, A61K2300/00 (EP);
A61K31/635, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/23] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | KOMBINIERTE HEMMUNG VON AMINOSÄURETRANSPORTERN ZUR HEMMUNG DER AKTIVITÄT VON MENSCHLICHER PLASMACYTOIDER DENDRITISCHER ZELLEN WÄHREND DER AUTOIMMUNITÄT | [2022/23] | English: | COMBINED INHIBITION OF AMINO ACID TRANSPORTERS FOR INHIBITING HUMAN PLASMACYTOID DENDRITIC CELL ACTIVITY DURING AUTOIMMUNITY | [2022/23] | French: | INHIBITION COMBINÉE DE TRANSPORTEURS D'ACIDES AMINÉS POUR INHIBER L'ACTIVITÉ DE CELLULES DENDRITIQUES PLASMACYTOÏDES HUMAINES PENDANT L'AUTO-IMMUNITÉ | [2022/23] | Examination procedure | 22.06.2022 | Despatch of communication that the application is refused, reason: Examination on filing A.90(5) [2022/45] | 02.07.2022 | Application refused, date of legal effect [2022/45] |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]EP2599771 (DAITO CHEMIX CORP [JP], et al) [Y] 1-15 * paragraph [0550]; example 110 * * claim 9 *; | [XYI] - O'DELL J R ET AL, "Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications", THE NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, (19960101), vol. 334, no. 20, ISSN 0028-4793, pages 1287 - 1291, XP008141323 [X] 1-4,7,9-11,15 * the whole document * * abstract * * page 1289, column r, paragraph 2 - page 1290, column r, paragraph 2; table 1 * [Y] 1-15 [I] 5,6,8,12-14 | [XYI] - CAPELL HILARY A ET AL, "Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, GB, (20070201), vol. 66, no. 2, doi:10.1136/ARD.2006.057133, ISSN 0003-4967, pages 235 - 241, XP009144586 [X] 1-4,7,9-11,15 * the whole document * * abstract * * page 239, column l, paragraph 5 - page 240, column r, paragraph 2 * [Y] 1-15 [I] 5,6,8,12-14 DOI: http://dx.doi.org/10.1136/ard.2006.057133 | [XI] - SCHIPPER L. G. ET AL, "Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs", RHEUMATOLOGY, GB, (20090701), vol. 48, no. 7, doi:10.1093/rheumatology/kep090, ISSN 1462-0324, pages 828 - 833, XP055802846 [X] 1-4,7,9-11,15 * the whole document * * abstract * * page 828, column r, paragraph l - page 829, column l, paragraph 1 * * page 830, column l, paragraph l - page 832, column l, paragraph l * [I] 5,6,8,12-14 DOI: http://dx.doi.org/10.1093/rheumatology/kep090 | [Y] - KOTYLA PRZEMYSLAW J. ET AL, "Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, (20201007), vol. 21, no. 19, doi:10.3390/ijms21197390, page 7390, XP055801976 [Y] 1-15 * the whole document * * abstract * DOI: http://dx.doi.org/10.3390/ijms21197390 | [Y] - GREMESE ELISA ET AL, "JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy", JOURNAL OF LEUKOCYTE BIOLOGY, GB, vol. 106, no. 5, doi:10.1002/JLB.5RU0519-145R, ISSN 0741-5400, (20191101), pages 1063 - 1068, URL: https://jlb.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/JLB.5RU0519-145R, XP055801977 [Y] 1-15 * the whole document * * abstract * * figure 2 * DOI: http://dx.doi.org/10.1002/JLB.5RU0519-145R | [YD] - NEHSER M ET AL, "System XAntiporter Inhibitors: Azo-Linked Amino-Naphthyl-Sulfonate Analogues of Sulfasalazine", NEUROCHEMICAL RESEARCH, PLENUM PRESS, NEW YORK, US, vol. 45, no. 6, doi:10.1007/S11064-019-02901-6, ISSN 0364-3190, (20191121), pages 1375 - 1386, (20191121), XP037151321 [YD] 1-15 * the whole document * * abstract * * tables 1-2 * DOI: http://dx.doi.org/10.1007/s11064-019-02901-6 | [YD] - PATEL DHAVALKUMAR ET AL, "Novel analogs of sulfasalazine as system x c - antiporter inhibitors: Insights from the molecular modeling studies", DRUG DEVELOPMENT RESEARCH., US, vol. 80, no. 6, doi:10.1002/ddr.21557, ISSN 0272-4391, (20190614), pages 758 - 777, URL: https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ddr.21557, XP055801828 [YD] 1-15 * the whole document * * abstract * * table 1 * * page 773, column r, paragraph l - page 775, column l, paragraph 2 * DOI: http://dx.doi.org/10.1002/ddr.21557 | [Y] - KRUPA SHUKLA ET AL, "Inhibition oftransporter-mediated cystine uptake by sulfasalazine analogs", BIORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM , NL, vol. 21, no. 20, doi:10.1016/J.BMCL.2011.07.081, ISSN 0960-894X, (20110722), pages 6184 - 6187, (20110812), XP028295470 [Y] 1-15 * the whole document * * table 1 * DOI: http://dx.doi.org/10.1016/j.bmcl.2011.07.081 | [Y] - ANGELINI JACOPO ET AL, "JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future", BIOMOLECULES, vol. 10, no. 7, doi:10.3390/biom10071002, (20200705), page 1002, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408575/pdf/biomolecules-10-01002.pdf, XP055801970 [Y] 1-15 * the whole document * * abstract * * table 1 * * page 9, line 1 - page 21, line 4 * DOI: http://dx.doi.org/10.3390/biom10071002 | [Y] - BARRAT FRANCK J. ET AL, "A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infection", JOURNAL OF EXPERIMENTAL MEDICINE, US, vol. 216, no. 9, doi:10.1084/jem.20181359, ISSN 0022-1007, (20190902), pages 1974 - 1985, URL: https://rupress.org/jem/article-pdf/216/9/1974/1172319/jem_20181359.pdf, XP055802842 [Y] 1-15 * the whole document * * abstract * * table 1 * * page 1977, column r, paragraph 1 - page 1978, column l, paragraph 2 * * page 1980, column r, paragraph 3 - page 1981, column r, paragraph l * DOI: http://dx.doi.org/10.1084/jem.20181359 | [Y] - NAKAGAWA HIDEMI ET AL, "Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis", JOURNAL OF DERMATOLOGY., JP, vol. 47, no. 2, doi:10.1111/1346-8138.15173, ISSN 0385-2407, (20191209), pages 114 - 120, URL: https://onlinelibrary.wiley.com/doi/full-xml/10.1111/1346-8138.15173, XP055803724 [Y] 1-15 * the whole document * * abstract * * page 114, column l, paragraph l - page 115, column l, paragraph 1 * * page 117, column r, paragraph l - page 119, column l, line 2 * DOI: http://dx.doi.org/10.1111/1346-8138.15173 | by applicant | - CAS , no. 285986-31-4 | - PANDA et al., Curr Opin Immunol, (20170000), vol. 44, pages 20 - 25 | - LARRAUFIE et al., Bioorg Med Chem Lett, (20150000), vol. 25, no. 21, pages 4787 - 4792 | - Neurochemical research, (20200000), vol. 45, page 1375 | - PATEL, Drug Dev Res, (20190000), vol. 80, pages 758 - 777 | - NAPOLITANO et al., Biochemical Pharmacology, (20170000), vol. 143, pages 39 - 52 | - JUEN et al., J. Med. Chem., (20170000), vol. 60, no. 14, pages 6119 - 6136 | - WINGELHOFER et al., Leukemia, (20180000), vol. 32, pages 1135 - 1146 | - MULLER et al., Chembiochem, (20080000), vol. 9, no. 5, pages 723 - 727 | - PAGE et al., J. Med. Chem., (20120000), vol. 55, no. 3, pages 1047 - 1055 | - CHIEN et al., Chemico-Biological Interactions, (20080000), vol. 176, no. 1, pages 40 - 47 | - NELSON et al., Blood, (20110000), vol. 117, no. 12, pages 3421 - 3429 | - WILLS, Anal Chem, (20170000), vol. 89, pages 9616 - 9619 | - ARAZI, Nat. Immunol., (20190000), vol. 20, pages 902 - 914 | - STUART, Cell, (20190000), vol. 177, pages 1888 - 1902 | - MCLNNES, Journal of Open Source Software, (20180000), vol. 3, no. 29, page 861 | - CONWAY, Bioinformatics, (20170000), vol. 33, pages 2938 - 2940 | - SCHMIDL et al., Blood, (20140000), vol. 123, pages 68 - 78 | - ZHANG et al., Genome Biol, (20080000), vol. 9, page R137 |